ICOC Committed funds:
Awards as PI
|Disease Team Research I||Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells||$19,999,996|
|Tools and Technologies II||Antibody tools to deplete or isolate teratogenic, cardiac, and blood stem cells from hESCs||$1,869,487|
|Comprehensive Grant||Prospective isolation of hESC-derived hematopoietic and cardiomyocyte stem cells||$2,636,900|
E2A proteins maintain the hematopoietic stem cell pool and promote the maturation of myelolymphoid and myeloerythroid progenitors.
Overexpression of BCL2 enhances survival of human embryonic stem cells during stress and obviates the requirement for serum factors.
Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature.
Prospective isolation of human embryonic stem cell-derived cardiovascular progenitors that integrate into human fetal heart tissue.